English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the current study, efforts are being made to formulate transdermal salbutamol-cubosomal gel to manage paediatric asthma. Salbutamol-loaded cubosomal gels were prepared by melt emulsification and sonication. The cubosomal gels were characterised by morphology, particle size, zeta potential, entrapment efficacy, assay, viscosity, and texture profiles.  Ex vivo  permeation and pharmacokinetic studies were performed using rats. The mean cubosomal particle size (208–361 ± 12.5–32.5 nm), PDI (0.06–0.11 ± 0.01–0.02), viscosity (8527–9019 cp), and entrapment efficacy (76.3–91.0% w/w) increase with the level of monoolein. The  ex vivo  permeation study showed a biphasic release pattern, with salbutamol cleared from control gel within 8 h, while cubosomal gels showed sustained release up to 72 h. The pharmacokinetic profiles in the rat model showed 8.62-fold higher bioavailability with cubosomal gel. The study demonstrated the potential of cubosomal nanoparticle-laden gel to sustain the release of salbutamol to treat paediatric asthma.

Sustained delivery of salbutamol from cubosomal gel for management of paediatric asthma: in vitro and in vivo evaluation